Department of Health – Abu Dhabi signs a Memorandum of Understanding with Microsoft to create an AI-powered Population Health Intelligence framework
Abu Dhabi, UAE: Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has signed a Memorandum of Understanding (MoU) with Microsoft to co-develop an advanced 'Population Health Intelligence' framework – a world's first true learning health system. Signed at Abu Dhabi Global Health Week (ADGHW), the framework aims to create a true learning health system capable of continuously predicting, preventing, and responding to public health challenges.
The MoU was signed by H.E. Ibrahim Al Jallaf, Executive Director of Digital Health at DoH and Naim Yazbeck, Country General Manager from Microsoft UAE.
Around the world, fragmented data systems and reactive models are failing to meet the rising demands for treating complex chronic conditions. As health systems worldwide focus towards shifting from reactive to predictive models, Abu Dhabi is taking a bold step forward, turning billions of data points into life-changing insights driven by artificial intelligence (AI) and advanced analytics into actionable interventions at the individual and population level.
The 'Population Health Intelligence' framework is built on two interconnected pillars:
Predict: Establish a digital twin of Abu Dhabi that consolidates clinical, behavioural, environmental and demographic data into a unified view, enabling AI to proactively detect and address health anomalies for early investigation.
Prevent and Act: Deploy AI-powered, context-aware recommendations tailored to population, district, and individual levels; simulate the future impact of interventions; and enable coordinated response based on real-time feedback.
In line with its commitment to ensuring the highest standards of data protection, DoH guarantees that all patient data will be handled with the utmost confidentiality and security. This initiative adheres to robust privacy regulations, ensuring that sensitive information is safeguarded against unauthorized access and breaches. By embedding intelligence into every layer of the health system, the framework supports Abu Dhabi's objective to shift from reactive care to proactive healthspan for all.
Commenting on the announcement, H.E. Ibrahim Al Jallaf said: 'Our mission goes beyond delivering healthcare, we are shaping a new era of longevity, where data, prevention, and innovation come together to empower healthier lives. Through advanced technologies, global collaboration, and bold policy thinking, we are building a resilient health ecosystem that anticipates needs, addresses disparities, and unlocks the full potential of every individual. Abu Dhabi is proud to lead the charge in redefining what health systems can achieve when informed by data-led insights, and driven by purpose.'
Through this collaboration, DoH will leverage Microsoft's trusted and secure cloud platforms and AI technologies to span multiple workstreams, including concept and prototype development, value assurance, integration of the framework into Abu Dhabi's existing digital health ecosystem, and knowledge-sharing in the public domain through conferences and global reports.
Commenting on the intent of this partnership, Mr. Yazbeck said: 'This collaboration reflects the transformative potential of artificial intelligence and cloud technologies in solving some of the world's most pressing healthcare challenges. By enabling secure, real-time insights across population-level data, we are partnering with the Department of Health – Abu Dhabi to build the digital foundations of a more predictive, personalised, and resilient healthcare system. Together, we are driving innovation that places data and intelligence at the heart of proactive care.'
The 'Population Health Intelligence' framework will focus on key population health challenges including chronic disease prevention, early detection, and health equity. Reflecting Abu Dhabi's commitment to global impact, DoH will share relevant insights and innovations from this collaboration in the public domain, supporting the development of similar models worldwide.
ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care.
Four core themes guided discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being.
About Abu Dhabi Global Health Week:
Abu Dhabi Global Health Week (ADGHW) is a major government-led initiative by the Department of Health – Abu Dhabi (DoH). It drives transformative innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being'. ADGHW serves as a year-round 'always-on' platform with a proactive approach centred around preventive, personalised, and holistic care. Held with and for the world, ADGHW is a platform for open, inclusive exchange, and joint action.
ADGHW welcomes entrepreneurs, policymakers, researchers, innovators, and investors to transform ideas into action, and collaborate around topics like advancing precision care and building a resilient technology-driven ecosystem. ADGHW 2025 proudly collaborates with key strategic partners, including Foundation Partner, M42 and Global Health and Longevity Champion, PureHealth. Additional exhibitors and sponsors include Burjeel, GSK, Johnson & Johnson, Lilly, Microsoft, Novo Nordisk, Viatris, Novartis, Roche, Cleveland Clinic Abu Dhabi, Deloitte, Gilead, Juvenescence, NYU Abu Dhabi and Pfizer, united in their commitment to advancing the future of healthcare and life sciences.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
2 days ago
- Mid East Info
The Department of Health – Abu Dhabi and Abbott Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi - Middle East Business News and Information
During BIO International Convention in Boston USA, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Abbott, the global healthcare leader, entered a landmark partnership to localise manufacturing of pharmaceuticals in Abu Dhabi and advance digital health solutions. Leveraging Abu Dhabi's advanced life sciences infrastructure, this milestone reflects the emirate's proactive preparedness to reduce dependency on imports, strengthen supply chain resilience, and foster a sustainable, self-sufficient healthcare ecosystem. H.E. Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: 'Following the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi, the emirate proved to be equipped with a holistic, integrated infrastructure that fosters local manufacturing and R&D, positioning it as a regional healthcare gateway and leader in life sciences. By integrating our strategic vision with Abbott's expertise, we aim to accelerate the development and deployment of innovative healthcare products and solutions, reducing time-to-market, improving healthcare outcomes, and ensuring that breakthrough therapies reach patients faster. This approach positions Abu Dhabi as a regional leader in fostering an agile, innovation-driven healthcare ecosystem that directly translates scientific advancements into tangible benefits for our community.' The strategic collaboration outlines a comprehensive plan focusing on four key pillars including localisation of Abbott's pharmaceutical portfolio, biosimilar development, digital transformation through electronic patient information leaflets, and a robust education and workforce development initiative. Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant said: 'Abbott is proud to announce a strategic collaboration with the Department of Health – Abu Dhabi, aimed at advancing healthcare resilience and innovation in Abu Dhabi. Building on Abbott's long-standing commitment to the UAE's healthcare system, this partnership will focus on localising existing pharmaceutical products, and jointly exploring the development of biosimilars, supported by regulatory alignment. The collaboration also includes initiatives to digitise life science product information through electronic leaflets in alignment with the UAE's digital health strategy. Another key component of this collaboration is the development of education programs to build local capabilities. Additionally, Abbott and the Department of Health will evaluate opportunities for joint research and development to strengthen long-term healthcare sustainability in the UAE.' Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 to 21, 2025. The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions.
Mid East Info
6 days ago
- Mid East Info
DoH and Boehringer Ingelheim Ink Strategic Partnership to Advance Life Science Innovation Across the Emirate
On the sidelines of a high-profile Abu Dhabi delegation visit to the USA Abu Dhabi, United Arab Emirates,June 2025: The Department of Health – Abu Dhabi DoH, the regulator of the healthcare sector in Abu Dhabi, signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim , one of the world's leading research-driven pharmaceutical companies. This strategic partnership aims to advance scientific research and innovation, foster groundbreaking research and development and cultivate an environment of scientific excellence, further cementing the Emirate as the MENA region's premier hub for healthcare, life sciences and innovation. In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at BI, the agreement was signed during BIO International Convention in Boston at the Abu Dhabi Pavilion by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at BI. Through this strategic partnership, the two parties seek to strengthen the Emirate's research ecosystem by facilitating access to and harnessing the capabilities of Boehringer Ingelheim's OpnME platform. Researchers, scientists and innovators across Abu Dhabi will be able to leverage the platform's cutting-edge data and resources to address critical biological challenges and accelerate scientific discovery. Through four flagship programmes, Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e) and opnTALENTS (o25), the platform empowers the research community with access to advanced compounds, collaborative opportunities, expert networks and support for emerging talent. OpnME connects visionary researchers to champion transformative, research-driven medical innovation for generations to come. In line with Abu Dhabi's vision to shape the future of healthcare, this partnership between DoH and BI enhances knowledge exchange and invests in local talent. It offers scientists a purpose-driven, globally connected environment to lead impactful research, further reinforcing the Emirate's commitment to transforming the regional healthcare ecosystem through science and technology. Dr. Asma Ibrahim Al Mannaei, the Executive Director of the Health Life Sciences Sector at DoH, said: 'Our partnership with Boehringer Ingelheim reflects our commitment to pioneering innovation and scientific research as parts of our efforts to advance health outcomes and improve the quality of life for communities around the world. We're empowering Abu Dhabi researchers with the opnMe platform, an open portal offering top-tier pharmaceutical compounds, fostering collaboration and safeguarding researchers' rights to their findings. This is about transforming our emirate into a global life sciences hub, speeding up breakthroughs, and building a healthier, resilient future for all. Ousama Alhaj, General Manager and Head of Human Pharma for Near East and UAE at Boehringer Ingelheim, said: 'At Boehringer Ingelheim, we are proud to partner with the Department of Health – Abu Dhabi (DoH) to empower the scientific community through our OpnMe platform. This collaboration reflects our shared commitment to advancing research and innovation in the region, fostering a culture of discovery, and ultimately improving patient outcomes. By providing access to our scientific resources, including advanced compounds, collaborative research opportunities, and expert networks, we aim to inspire new ideas and support the next generation of researchers in Abu Dhabi.' Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 14 to 21, delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions.
Mid East Info
15-06-2025
- Mid East Info
Abu Dhabi Reinforces Global Leadership in Healthcare Innovation with High-Level U.S. Visit - Middle East Business News and Information
Strategic mission to the U.S. aims to strengthen partnerships and showcase Abu Dhabi's excellence in life sciences and precision medicine Abu Dhabi, United Arab Emirates – June 2025: A high-level delegation led by the Department of Health – Abu Dhabi (DoH), is set to embark on a strategic mission to the United States from June 14 to 21, 2025. The visit reaffirms Abu Dhabi's global leadership in healthcare innovation and reflects its broader vision for healthcare transformation—driven by innovation, investment, and a deep commitment to global collaboration. The delegation will visit key U.S. cities including Boston, Washington D.C., and Philadelphia, in parallel with Abu Dhabi's participation at BIO International Convention 2025 , one of the world's foremost biotechnology events. The visit will spotlight the Emirate's achievements in AI, digital health, genomics, and clinical research and showcase Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Life Science Cluster, while promoting long-term strategic partnerships with government entities, research institutions, and global innovators. H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, stated: 'This mission reflects our commitment to shaping the future of health through collaboration, innovation, and shared purpose. Our vision is to build a health system that predicts, prevents, acts to restore, and acts to cure, therefore ensuring better outcomes for our communities and beyond. This can only be achieved through meaningful partnerships and a shared ambition to improve lives. We are proud to join our partners in the United States to explore new opportunities that advance healthcare, both in the UAE and globally.' The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities, and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo. Abu Dhabi continues to lead the region in genomics through the Emirati Genome Programme, which has successfully sequenced over 800,000 samples, creating one of the most advanced national genomic databases. The Emirate is also home to more than 90 licensed research centers and 30+ ongoing clinical trials in areas such as oncology, rare diseases, and chronic conditions. Advanced data platforms such as Malaffi, which securely store over 5 million patient records—enable AI-powered insights and real-world evidence, while national initiatives like the Golden Visa program are cultivating a global workforce and have granted over 2,000 long-term visas for researchers and healthcare professionals from around the world.
